$119.09−1.18 (−0.98%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Incyte (INCY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~14.5%/yr (FY21→FY25), net margin 25.0%, and free cash flow (~$1.4B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲21.2%
5,141.2
FY21→FY25CAGR +14.5%/yr
Net income ($M)▲3845.0%
1,286.7
one-off year: see footnoteCAGR +7.9%/yr
Free cash flow ($M)▲443.9%
1,354.6
FY21→FY25CAGR +24.2%/yr
Diluted EPS▲4173.3%
6.41
buyback-liftedCAGR +10.7%/yr
What the receipts whisper · what a headline number hides
Share count
−9.6%
222.1mn → 200.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$58.9M
−31.8% YoY in FY25 · 1.1% of revenue.
Returns vs FCF
1%
$0.0B returned vs $1.4B of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
25¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 94.9% → 92.8%. Net margin 25.0% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 6,010.8 | 5,141.2 | 4,241.2 | 3,695.6 | 3,394.6 | 2,986.3 | ▲21.2% | +14.5% |
Cost of revenue | 439.4 | 372.1 | 312.1 | 255.0 | 207.0 | 151.0 | ▲19.2% | +25.3% |
Gross profit | 5,571.4 | 4,769.1 | 3,929.1 | 3,440.7 | 3,187.6 | 2,835.3 | ▲21.4% | +13.9% |
Research & development | 3,435.9 | 2,050.2 | 2,606.8 | 1,627.6 | 1,585.9 | 1,458.2 | ▼21.4% | +8.9% |
Selling, general & admin | 1,434.5 | 1,376.2 | 1,242.2 | 1,155.7 | 1,002.1 | 739.6 | ▲10.8% | +16.8% |
Total operating expenses | 4,944.8 | 3,254.3 | 3,867.8 | 2,820.1 | 2,608.2 | 2,249.5 | ▼15.9% | +9.7% |
Operating incomefeeds ROC rank | 626.5 | 1,514.9 | 61.4 | 620.5 | 579.4 | 585.8 | ▲2368.6% | +26.8% |
Other income, net | 169.7 | 149.6 | 255.3 | 213.7 | −50.3 | −15.3 | — | — |
Pretax income | 796.2 | 1,664.5 | 316.6 | 834.2 | 529.1 | 570.4 | ▲425.7% | +30.7% |
Income tax | 392.8 | 377.8 | 284.0 | 236.6 | 188.5 | −378.1 | ▲33.0% | +26.1% (22→25) |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 403.4 | 1,286.7 | 32.6 | 597.6 | 340.7 | 948.6 | ▲3845.0% | +7.9% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.88 | 6.41 | 0.15 | 2.65 | 1.52 | 4.27 | ▲4173.3% | +10.7% |
Diluted shares (mn) | 203.25 | 200.70 | 210.53 | 225.93 | 223.96 | 222.07 | ▼4.7% | −2.5% |
| Margins | ||||||||
Gross margin88th pct in Healthcare | 92.7% | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% | ▲0.1pp | −2.2pp |
Operating margin | 10.4% | 29.5% | 1.4% | 16.8% | 17.1% | 19.6% | ▲28.0pp | +9.8pp |
Net margin59th pct in Healthcare | 6.7% | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | ▲24.3pp | −6.7pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −66% vs a 28% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 90% vs a 28% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-10 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Incyte's revenue last fiscal year?
Incyte reported revenue of $5,141.2M in fiscal 2025, up 21.2% from fiscal 2024.
What was Incyte's net income?
Incyte reported net income of $1,286.7M in fiscal 2025, a net margin of 25.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

